Apple: Consensus Estimates For Q2 2021

Apple (NASDAQ: AAPL) will be reporting their fiscal second quarter on April 28th after market close. Analysts have a consensus $152 12-month price target on the company, via a total of 40 analysts, with 11 analysts having strong buy ratings. 21 analysts meanwhile have buy ratings, 6 have hold ratings, one analyst has a sell rating, and one has a strong sell on the company. The street high comes from Evercore ISI with a $175 price target, and the lowest target sits at $83.

27 analysts have revenue estimates for the second quarter. The mean revenue estimate between all 27 analysts is $76.87 billion; this number has been revised upwards from $74 billion at the start of the year. The highest revenue estimate is $83.2 billion, while the lowest is $70.9 billion.

Onto EBITDA estimates, there are currently only 10 analysts who have second-quarter EBITDA estimates. The mean is currently $22.5 billion, with this number having been revised down from $20.2 billion at the start of the year. Street high is a $23.9 billion EBITDA estimate and the lowest is $20.3 billion.

Analysts estimate that quarterly earnings per share will come in at $0.98, with this number being slightly revised up from $0.90 at the start of the year. Street high is currently $1.09 and the lowest estimate is $0.85 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Giant Is Building 1.5 Million More Ounces a Year | Agnico Eagle Q3 Earnings

This Gold Giant Was a Mess. Now It’s Back! | Barrick Mining Q3 2026 Earnings

Who’s Making Money at $4,000 Gold? | Munich Mining Conference Day 2

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM

Canaccord Reiterates Columbia Care As A Cannabis Top Pick

Columbia Care (NEO: CCHW) reported its first quarter financial results on May 17th. The company...

Thursday, May 20, 2021, 04:41:00 PM

Kinross Sees BMO Lower Target To $11 Following Earnings

On February 16th, Kinross Gold Corp (TSX: K) put out a number of news releases,...

Friday, February 18, 2022, 04:36:00 PM

Aurora Cannabis: Stifel Lowers Rating To Hold, Price Target Falls To $10.50 From $16

Yesterday, Aurora Cannabis (TSX: ACB) (NYSE: ACB) provided a business update. The firm announced that...

Wednesday, September 9, 2020, 01:47:00 PM

Amazon: Analyst Consensus Points To $4.02 Earnings Per Share For Q4

Amazon.com Inc (NASDAQ: AMZN) will be reporting its fiscal fourth quarter financial results on February...

Tuesday, February 1, 2022, 03:48:00 PM